A computation-aided drug design yielded an NKCC1-specific inhibitor (ARN23746) that holds great promise in preclinical studies for the treatment of brain disorders, because, unlike bumetanide, it can cross the BBB to antagonize NKCC1 within the brain [54]. Here, SLC12A2 is linked to brain disorder.